| Title |
Cancer survival in adult patients in Spain. Results from nine population-based cancer registries
|
|---|---|
| Published in |
Clinical and Translational Oncology, July 2017
|
| DOI | 10.1007/s12094-017-1710-6 |
| Pubmed ID | |
| Authors |
M. D. Chirlaque, D. Salmerón, J. Galceran, A. Ameijide, A. Mateos, A. Torrella, R. Jiménez, N. Larrañaga, R. Marcos-Gragera, E. Ardanaz, M. Sant, P. Minicozzi, C. Navarro, M. J. Sánchez, the REDECAN Working Group |
| Abstract |
With the aim of providing cancer control indicators, this work presents cancer survival in adult (≥15 years) patients in Spain diagnosed during the period 2000-2007 from Spanish cancer registries participating in the EUROCARE project. Cancer cases from nine Spanish population-based cancer registries were included and analysed as a whole. All primary malignant neoplasms diagnosed in adult patients were eligible for the analysis. Cancer patients were followed until 31 December 2008. For each type of cancer, 1-, 3- and 5-year observed and relative survival were estimated by sex, age and years from diagnosis. Furthermore, age-standardized 5-year relative survival for the period 2000-2007 has been compared with that of the period 1995-1999. Skin melanoma (84.6 95% CI 83.0-86.2), prostate (84.6% 95% CI 83.6-85.6) and thyroid (84.2% CI 95% 82.0-86.6) cancers showed the highest 5-year relative survival, whereas the worst prognosis was observed in pancreatic (6% 95% CI 5.1-7.0) and oesophageal (9.4% 95% CI 7.9-11.1) cancers. Overall, survival is higher in women (58.0%) than in men (48.9%). The absolute difference in relative survival between 2000-2007 and 1995-1999 was positive for all cancers as a whole (+4.8% in men, +1.6% in women) and for most types of tumours. Survival increased significantly for chronic myeloid leukaemia, non-Hodgkin's lymphoma and rectum cancer in both sexes, and for acute lymphoid leukaemia, prostate, liver and colon cancers in men and Hodgkin's lymphoma and breast cancer in women. Survival patterns by age were similar in Europe and Spain. A decline in survival by age was observed in all tumours, being more pronounced for ovarian, corpus uteri, prostate and urinary bladder and less for head and neck and rectum cancers. High variability and differences have been observed in survival among adults in Spain according to the type of cancer diagnosed, from above 84% to below 10%, reflecting high heterogeneity. The differences in prognosis by age, sex and period of diagnosis reveal opportunities for improving cancer care in Spain. |
X Demographics
The data shown below were collected from the profiles of 41 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 6 | 15% |
| Mexico | 4 | 10% |
| Venezuela, Bolivarian Republic of | 3 | 7% |
| Colombia | 2 | 5% |
| France | 1 | 2% |
| Norway | 1 | 2% |
| Chile | 1 | 2% |
| Tuvalu | 1 | 2% |
| El Salvador | 1 | 2% |
| Other | 5 | 12% |
| Unknown | 16 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 38 | 93% |
| Practitioners (doctors, other healthcare professionals) | 3 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 143 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 143 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 32 | 22% |
| Student > Bachelor | 16 | 11% |
| Other | 15 | 10% |
| Student > Doctoral Student | 11 | 8% |
| Student > Master | 10 | 7% |
| Other | 25 | 17% |
| Unknown | 34 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 35% |
| Nursing and Health Professions | 13 | 9% |
| Biochemistry, Genetics and Molecular Biology | 11 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
| Immunology and Microbiology | 3 | 2% |
| Other | 20 | 14% |
| Unknown | 40 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 January 2022.
All research outputs
#1,072,118
of 23,954,688 outputs
Outputs from Clinical and Translational Oncology
#21
of 1,387 outputs
Outputs of similar age
#21,016
of 285,649 outputs
Outputs of similar age from Clinical and Translational Oncology
#1
of 33 outputs
Altmetric has tracked 23,954,688 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,387 research outputs from this source. They receive a mean Attention Score of 3.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,649 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.